According to a report by Wallstreet-online on January 13th, Luxembourg investment company Reinet Investments SCA (hereinafter referred to as "Reinet") recently announced that its subsidiary Reinet Jersey Holdings Limited (hereinafter referred to as "RJHL") has signed a secondary bulk trading agreement with investment bank company J.P. Morgan Securities plc (hereinafter referred to as "JP Morgan"). Under the agreement, RJHL will sell 43,310,286 shares of British American Tobacco (BAT) common stock, representing approximately 1.96% of BAT's issued common stock (excluding treasury stock as of the close of trading on January 10, 2025).
The stock sale will be conducted through an accelerated bookbuilding process, with the sale price and number of shares sold determined based on the results of the process. Following the announcement, the accelerated bookbuilding process will start immediately and may end swiftly at any time. Further announcements will be made after the completion of the transaction. The completion of this transaction is contingent upon market demand, price, and market conditions.
In addition, in November and December of 2024, RJHL sold 5 million shares of BAT common stock through a gradual selling program on the London Stock Exchange, resulting in total proceeds of approximately £148.5 million. J.P. Morgan acted as the sole global coordinator and bookrunner in this large transaction.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
